骨关节炎
医学
基质金属蛋白酶
软骨
药理学
炎症
金属蛋白酶
非甾体
临床试验
基质金属蛋白酶抑制剂
生物信息学
内科学
病理
生物
解剖
替代医学
作者
Yichao Wan,Wei Li,Liao Zhi-peng,Mi Yan,Xuwang Chen,Zilong Tang
标识
DOI:10.2174/0929867326666181217153118
摘要
Osteoarthritis (OA) is an age-related degenerative disease, which is characterized by chronic joint pain, inflammation and the damage of joint cartilage. At present, steroidal drugs and nonsteroidal anti-inflammatory drugs (NSAIDS), selective cyclooxygenase-2 (COX-2) inhibitors, are the first-line drugs for the treatment of OA. However, these drugs could lead to some cardiovascular side effects. Therefore, it is urgent to develop novel agents for the treatment of OA. Matrix metalloproteinase-13 (MMP-13), an important member of matrix metalloproteinases (MMPs) family, plays a vital role by degrading type II collagen in articular cartilage and bone in OA. It is noted that MMP-13 is specially expressed in the OA patients, and not in normal adults. In addition, broadspectrum MMP inhibitors could result in some painful and joint-stiffening side effects, called musculoskeletal syndrome (MSS) in the clinical trials. Thus, developing selective MMP-13 inhibitors is a potential strategy for the therapy of OA. In this review, we summarize the recent progress of selective MMP-13 inhibitors including two subfamilies, namely zinc-binding and non-zinc-binding selective MMP-13 inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI